AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

The employee equity award is subject to the terms of the inducement plan and its restricted stock unit agreement.

Rhea-AI Summary

AEON Biopharma (AEON) granted restricted stock units covering 150,000 common shares to one newly hired non-executive employee as an employment inducement. The Compensation Committee approved the award on October 5, 2026, under the 2025 Employment Inducement Incentive Award Plan. The units, which are equity awards, vest in four equal installments: 25% on each annual anniversary of March 9, 2026.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units covering 150,000 common shares create potential dilution as the employee award vests.

Argus 15 min delay 16 alerts

+0.25% vs previous close $0.28 last price 1.0x rel. volume Open Argus

Details

Market Reaction – AEON

$0.28 – $0.33 Day Range

$13.86M Market Cap

On Oct 9, the day this news came out, the latest delayed price for AEON is 0.25% above the previous close. Our momentum scanner has recorded 16 alerts for this stock so far that day. The latest delayed price is $0.28.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Shares covered by RSUs: 150,000 shares Vesting schedule: 4 equal installments; 25% each

Shares covered by RSUs

150,000 shares

Grant to one newly hired non-executive employee

Vesting schedule

4 equal installments; 25% each

On each annual anniversary of March 9, 2026

Key Terms

restricted stock units

1 terms

restricted stock units financial

"grant of restricted stock units (“RSUs”) covering 150,000 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALISO VIEJO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX^® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported the grant of restricted stock units (“RSUs”) covering 150,000 shares of the Company’s common stock to one newly hired non-executive employee of the Company. The award was approved by the Company’s Compensation Committee of the Board of Directors on October 5, 2026 under the Company’s 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of the Company. The RSUs vest in four equal installments, 25% on each annual anniversary of March 9, 2026. The award is subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant. The RSUs were granted as a material inducement to the employee’s entering into employment with the Company in accordance with Section 711 of NYSE American LLC Company Guide.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX^®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau^®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency for the manufacture of certain third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Contacts

Investor Contact:
Hershel Berry
Blueprint Life Science Group
hberry@bplifescience.com 

Source: AEON Biopharma

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What employee inducement award did AEON Biopharma grant?

AEON Biopharma granted restricted stock units covering 150,000 common shares to one newly hired non-executive employee. The award was a material inducement to entering employment with the company.

When does AEON Biopharma's employee inducement award vest?

The restricted stock units vest in four equal installments, with 25% vesting on each annual anniversary of March 9, 2026.